Quick Answer
LIFECORE BIOMEDICAL, INC. \DE\ reported Cash and Equivalents of $8.27 million for fiscal year 2025.
LIFECORE BIOMEDICAL, INC. \DE\ Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $8.27M | -2.3% |
| 2024 | $8.46M | -55.7% |
| 2023 | $19.09M | +547.2% |
| 2023 | $2.95M | -50.3% |
| 2022 | $5.94M | +133.8% |
| 2022 | $2.54M | +156.3% |
| 2022 | $991.0K | -10.0% |
| 2022 | $1.10M | +80.8% |
| 2021 | $609.0K | -35.1% |
| 2021 | $939.0K | +23.1% |
| 2021 | $763.0K | -58.8% |
| 2021 | $1.85M | -25.2% |
| 2020 | $2.48M | +464.0% |
| 2020 | $439.0K | +21.9% |
| 2020 | $360.0K | -66.7% |
| 2019 | $1.08M | -62.7% |
| 2018 | $2.90M | -51.7% |
| 2017 | $6.00M | -39.8% |
| 2016 | $9.97M | -29.4% |
| 2015 | $14.13M | -0.8% |
| 2014 | $14.24M | +3.8% |
| 2013 | $13.72M | -38.1% |
| 2012 | $22.18M | +172.6% |
| 2011 | $8.13M | -70.8% |
| 2010 | $27.82M | -36.0% |
| 2009 | $43.46M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $18.86M | — | +128.1% |
| May 31, 2025 | $8.27M | -2.3% | +52.6% |
| February 28, 2025 | $5.42M | — | -42.7% |
| November 30, 2024 | $9.46M | — | +11.7% |
| May 31, 2024 | $8.46M | — | +186.8% |
| February 28, 2023 | $2.95M | +59.1% | -56.8% |
| November 30, 2022 | $6.83M | +526.0% | +61.8% |
| August 31, 2022 | $4.22M | +200.3% | +326.0% |
- LIFECORE BIOMEDICAL, INC. \DE\ showed a decrease of -2.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2009–2025 period, LIFECORE BIOMEDICAL, INC. \DE\’s cash and equivalents has declined by 81.0% (from $43.46 million to $8.27 million).
- The most recent figure is from LIFECORE BIOMEDICAL, INC. \DE\’s fiscal year 2025 report (Form 10-K), filed with the SEC on August 7, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: